Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transplantation, Heterologous | 10 | 2022 | 363 | 2.360 |
Why?
|
| Thrombocytopenia | 4 | 2022 | 183 | 1.710 |
Why?
|
| Graft Survival | 8 | 2022 | 884 | 1.300 |
Why?
|
| Heterografts | 4 | 2017 | 98 | 0.940 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 12 | 0.840 |
Why?
|
| Liver | 4 | 2022 | 1230 | 0.780 |
Why?
|
| Swine | 8 | 2022 | 555 | 0.780 |
Why?
|
| Galactosyltransferases | 2 | 2017 | 40 | 0.660 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 35 | 0.660 |
Why?
|
| Neuraminic Acids | 1 | 2017 | 10 | 0.630 |
Why?
|
| Animals, Genetically Modified | 6 | 2022 | 181 | 0.620 |
Why?
|
| Graft Rejection | 4 | 2021 | 1065 | 0.590 |
Why?
|
| Kidney Transplantation | 2 | 2024 | 849 | 0.560 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 248 | 0.550 |
Why?
|
| Lung Transplantation | 1 | 2017 | 175 | 0.540 |
Why?
|
| Membrane Cofactor Protein | 3 | 2017 | 10 | 0.470 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1268 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1373 | 0.340 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2207 | 0.320 |
Why?
|
| Gene Knockout Techniques | 2 | 2017 | 77 | 0.310 |
Why?
|
| Leukocytes | 2 | 2018 | 202 | 0.280 |
Why?
|
| Tissue Scaffolds | 2 | 2017 | 106 | 0.280 |
Why?
|
| Endothelial Cells | 3 | 2018 | 428 | 0.280 |
Why?
|
| Animals | 12 | 2022 | 26582 | 0.260 |
Why?
|
| Frailty | 1 | 2024 | 58 | 0.220 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.210 |
Why?
|
| Heme Oxygenase-1 | 1 | 2022 | 19 | 0.210 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 37 | 0.210 |
Why?
|
| Perfusion | 1 | 2022 | 203 | 0.200 |
Why?
|
| Transplant Recipients | 1 | 2021 | 122 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 509 | 0.170 |
Why?
|
| Humans | 14 | 2024 | 86643 | 0.160 |
Why?
|
| P-Selectin | 1 | 2018 | 13 | 0.160 |
Why?
|
| E-Selectin | 1 | 2018 | 30 | 0.160 |
Why?
|
| Extracorporeal Circulation | 1 | 2017 | 26 | 0.160 |
Why?
|
| CD55 Antigens | 1 | 2017 | 20 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 311 | 0.150 |
Why?
|
| Bile Ducts | 1 | 2016 | 59 | 0.150 |
Why?
|
| Lung Injury | 1 | 2017 | 47 | 0.150 |
Why?
|
| Inflammation | 1 | 2022 | 920 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2017 | 181 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2017 | 232 | 0.130 |
Why?
|
| Lung | 1 | 2021 | 1170 | 0.130 |
Why?
|
| After-Hours Care | 1 | 2014 | 8 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2017 | 265 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2014 | 93 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 685 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 350 | 0.110 |
Why?
|
| General Surgery | 1 | 2014 | 229 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 977 | 0.110 |
Why?
|
| United States | 3 | 2021 | 6672 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1169 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2017 | 705 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3640 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1376 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1195 | 0.100 |
Why?
|
| Risk Factors | 2 | 2018 | 5417 | 0.100 |
Why?
|
| Prognosis | 1 | 2018 | 3679 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2024 | 8489 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2017 | 297 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2014 | 1004 | 0.070 |
Why?
|
| Male | 5 | 2018 | 40965 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2024 | 166 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 6 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 44 | 0.050 |
Why?
|
| Papio | 1 | 2021 | 82 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2021 | 149 | 0.050 |
Why?
|
| Female | 3 | 2018 | 44532 | 0.050 |
Why?
|
| Middle Aged | 1 | 2018 | 25028 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 463 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 5210 | 0.040 |
Why?
|
| Kupffer Cells | 1 | 2017 | 13 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 410 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 702 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 108 | 0.040 |
Why?
|
| CD40 Antigens | 1 | 2017 | 43 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2017 | 69 | 0.040 |
Why?
|
| Histocompatibility | 1 | 2017 | 71 | 0.040 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 48 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2017 | 127 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 69 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2017 | 44 | 0.040 |
Why?
|
| Allografts | 1 | 2017 | 172 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 213 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2018 | 420 | 0.040 |
Why?
|
| Albumins | 1 | 2016 | 133 | 0.040 |
Why?
|
| Neutrophils | 1 | 2018 | 307 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 18415 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 273 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 510 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 267 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2014 | 36 | 0.030 |
Why?
|
| Surgery Department, Hospital | 1 | 2014 | 42 | 0.030 |
Why?
|
| Workload | 1 | 2014 | 128 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 154 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1753 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2818 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 930 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 3990 | 0.020 |
Why?
|
| DNA | 1 | 2016 | 1294 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 369 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 428 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2232 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2261 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3241 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 7993 | 0.020 |
Why?
|